Welcome to our dedicated page for Chemomab Therapeutics Ltd. SEC filings (Ticker: CMMB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Chemomab Therapeutics Ltd. filings document a foreign private issuer focused on clinical-stage biotechnology and traded through American Depositary Shares. Its Form 6-K reports furnish operating updates, quarterly and year-end financial results, unaudited consolidated financial statements, management discussion and analysis, and press releases on the nebokitug program in primary sclerosing cholangitis.
The filing record also covers ADS and capital-structure matters, including at-the-market offering arrangements, ADS ratio-adjustment disclosures, shelf registration and equity incentive registration references, and annual general meeting materials. Proxy-related filings describe shareholder voting procedures for ADS holders, director elections, compensation policy approval, authorized share capital amendments, auditor re-appointment, quorum matters, and governance under Israeli company law.
Chemomab Therapeutics Ltd. disclosed that individual investor Erik Otto, a Canadian citizen, has filed an amended Schedule 13G reporting a significant ownership stake in the company’s American Depositary Shares (ADSs).
Otto reports beneficial ownership of 385,000 ADSs, representing 6.3% of Chemomab’s ADSs, based on 6,155,117 ADSs outstanding as of November 20, 2025, as provided by the company. He has sole voting and sole dispositive power over all of these ADSs, meaning he alone can vote and decide when to sell them.
The filing is made on Schedule 13G/A, which is typically used for passive investors. Otto certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of Chemomab, and are not held in connection with any control-seeking transaction.
Chemomab Therapeutics Ltd. filed a Form 6-K as a foreign private issuer to furnish a press release titled “Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Corporate Update.” The press release is attached as Exhibit 99.1.
The company states that Exhibit 99.1 is incorporated by reference into its existing registration statements on Form F-3 and Form S-8. The report is signed on behalf of Chemomab by Chief Financial Officer Sigal Fattal.
Chemomab Therapeutics Ltd. is changing the ratio of its American Depositary Shares (ADSs) to ordinary shares. Each ADS, which currently represents twenty ordinary shares, will represent eighty ordinary shares after the change, effectively a one-for-four reverse ADS split for ADS holders. The ratio change will take effect on August 26, 2025.
The Company’s ADSs will continue to trade on the Nasdaq Capital Market under the ticker CMMB, with a new CUSIP number of 16385C203. The Bank of New York Mellon, as depositary bank, will exchange every four existing ADSs for one new ADS on the effective date. No new ADSs will be issued in connection with this adjustment, and any fractional ADS positions will be aggregated, sold by the depositary, and the net cash proceeds distributed to affected ADS holders.
Chemomab Therapeutics Ltd. furnished a Form 6-K for August 2025 reporting the inclusion of three exhibits related to its second quarter of 2025. The filing states it includes unaudited condensed consolidated financial statements for the three and six months ended June 30, 2025, the companys Managements Discussion and Analysis of financial condition and results of operations for those periods, and a press release dated August 14, 2025 titled "Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update." The exhibits (99.1, 99.2, 99.3) and interactive financial data files are designated and will be deemed incorporated by reference into specified Form F-3 and Form S-8 registration statements. The report is signed by the Chief Financial Officer, Sigal Fattal.
Chemomab Therapeutics Ltd. has a disclosed beneficial owner, Erik Otto, who holds 1,690,000 American Depositary Shares (ADSs), representing 8.1% of the ADS class. Each ADS represents twenty ordinary shares.
Mr. Otto reports sole voting and sole dispositive power over these ADSs and certifies the holdings were not acquired to change or influence control of the issuer. The ownership percentage is stated based on the issuer's count of outstanding ADSs.
Morgan Stanley and subsidiary file Schedule 13G/A (Amendment 1) for Chemomab Therapeutics (CMMB) covering an ownership change effective 07/31/2025.
- Morgan Stanley reports 13,213,260 ordinary shares/ADS held with shared voting & dispositive power, equal to 3.2 % of Chemomab’s outstanding class.
- Morgan Stanley & Co. LLC reports 9,275,360 shares (shared voting & dispositive power) representing 2.2 % of the class.
- Both filers certify that they have ceased to be beneficial owners of more than 5 % of the issuer’s equity, triggering this amendment.
- Reporting persons are classified as HC/CO (holding company) and BD/CO (broker-dealer) under Item 3.
- No other persons have sole voting or dispositive authority; all powers are shared within the Morgan Stanley reporting units.
- The filing includes a Joint Filing Agreement (Ex. 99.1) and Item 7 subsidiary information (Ex. 99.2).
The amendment signals a reduction of Morgan Stanley’s aggregate position below the 5 % regulatory threshold, though the group still retains a meaningful minority stake.
Schedule 13G filing dated 06/30/2025 shows Morgan Stanley and subsidiary Morgan Stanley & Co. LLC have exceeded the 5 % threshold in Chemomab Therapeutics Ltd. (CMMB).
- Morgan Stanley reports 32,282,680 ordinary shares/ADS, representing 8.4 % of the outstanding class.
- Morgan Stanley & Co. LLC separately holds 28,786,680 shares or 7.5 %.
- Both entities report shared voting and dispositive power; no sole authority is listed.
- Filed under Rule 13d-1(b) as a broker-dealer/holding company, signalling a passive investment rather than a control bid.
- Cover pages classify the parent as “HC, CO” and the subsidiary as “BD, CO.”
- Signatures by authorised signatory Christopher O’Hara are dated 08/07/2025.
The disclosure increases institutional visibility and liquidity for CMMB but contains no operational or strategic changes.